Liang Yi-Lynn, Zhao Peishen, Draper-Joyce Christopher, Baltos Jo-Anne, Glukhova Alisa, Truong Tin T, May Lauren T, Christopoulos Arthur, Wootten Denise, Sexton Patrick M, Furness Sebastian G B
Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, 3052, Australia.
School of Pharmacy, Fudan University, Shanghai 201203, China.
ACS Pharmacol Transl Sci. 2018 Jul 26;1(1):12-20. doi: 10.1021/acsptsci.8b00017. eCollection 2018 Sep 14.
Advances in structural biology have yielded exponential growth in G protein-coupled receptor (GPCR) structure solution. Nonetheless, the instability of fully active GPCR complexes with cognate heterotrimeric G proteins has made them elusive. Existing structures have been limited to nanobody-stabilized GPCR:Gs complexes. Here we present methods for enhanced GPCR:G protein complex stabilization via engineering G proteins with reduced nucleotide affinity, limiting Gα:Gβγ dissociation. We illustrate the application of dominant negative G proteins of Gαs and Gαi2 to the purification of stable complexes where this was not possible with wild-type G protein. Active state complexes of adenosine:A1 receptor:Gαi2βγ and calcitonin gene-related peptide (CGRP):CLR:RAMP1:Gαsβγ:Nb35 were purified to homogeneity and were stable in negative stain electron microscopy. These were suitable for structure determination by cryo-electron microscopy at 3.6 and 3.3 Å resolution, respectively. The dominant negative Gα-proteins are thus high value tools for structure determination of agonist:GPCR:G protein complexes that are critical for informed translational drug discovery.
结构生物学的进展使G蛋白偶联受体(GPCR)结构解析呈指数级增长。尽管如此,完全激活的GPCR与同源异源三聚体G蛋白复合物的不稳定性使其难以捉摸。现有结构仅限于纳米抗体稳定的GPCR:Gs复合物。在此,我们提出了通过改造核苷酸亲和力降低的G蛋白来增强GPCR:G蛋白复合物稳定性的方法,以限制Gα:Gβγ解离。我们展示了Gαs和Gαi2的显性负性G蛋白在纯化稳定复合物中的应用,而野生型G蛋白无法实现这一点。腺苷:A1受体:Gαi2βγ和降钙素基因相关肽(CGRP):CLR:RAMP1:Gαsβγ:Nb35的活性状态复合物被纯化至均一性,并在负染电子显微镜下保持稳定。它们分别适用于通过冷冻电子显微镜以3.6 Å和3.3 Å的分辨率进行结构测定。因此,显性负性Gα蛋白是激动剂:GPCR:G蛋白复合物结构测定的高价值工具,这对于明智的转化药物发现至关重要。